Literature DB >> 11840366

Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes.

Bruno Memoli1, Roberto Minutolo, Vincenzo Bisesti, Loredana Postiglione, Angela Conti, Luigi Marzano, Alfredo Capuano, Michele Andreucci, Mario M Balletta, Bruna Guida, Ciro Tetta.   

Abstract

Protein malnutrition, a condition associated with an albumin concentration less than 3.5 g/dL, has been shown to be a major risk factor for increased mortality in hemodialysis patients. The aim of this cross-over study was to evaluate the relationship between the type of membrane adopted and serum albumin changes by measuring peripheral blood mononuclear cells (PBMC) interleukin-6 (IL-6) release, serum albumin, and plasma concentrations of C-reactive protein (CRP) in 18 patients dialyzed with different membranes. During the study, all patients were dialyzed with cuprophan (CU), synthetically modified cellulosic (SMC) membrane (a new cellulosic membrane with lesser complement activation), and cellulose diacetate (CD) membrane, and have served as their own controls. IL-6 spontaneous release by PBMC resulted after 3 months of SMC (436.2 +/- 47.4 pg/mL) significantly (P < 0.05) reduced as compared with CU (569.3 +/- 24.5 pg/mL). This effect was more evident after 6 months of dialysis with SMC (220 +/- 35.3 pg/mL, P < 0.01 versus CU and versus 3 months of SMC). The passage to CD membrane was followed by a progressive new increase in the IL-6 PBMC release (332.3 +/- 30.7 after 3 months, and 351.2 +/- 35.8 pg/mL after 6 months, respectively) that, however, remained significantly (P < 0.05) lower than CU. The behavior of CRP plasma levels resembled that of IL-6 PBMC release (23.3 +/- 4.7 in CU, 11.0 +/- 2.1 after 3 months in SMC, and 7.9 +/- 1.5 after 6 months in SMC, respectively). IL-6 release values were positively correlated with circulating levels of CRP (r = 0.3264, P < 0.002). Serum albumin increased after 6 months of dialysis with SMC membranes (3.25 +/- 0.09 g/dL in CU and 3.64 +/- 0.07 g/dL in SMC, P < 0.05). When the patients were switched to CD, serum albumin showed a slight, though not statistically significant, decrease. Serum albumin concentrations negatively correlated with both IL-6 release values (r = -0.247, P < 0.05) and CRP plasma levels (r = -0.433, P < 0.001). In conclusion, our data clearly show that a significant relationship exists between biocompatibility of the membranes and serum albumin changes; serum albumin levels, in fact, are negatively correlated with the PBMC spontaneous IL-6 release values and CRP circulating levels. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840366     DOI: 10.1053/ajkd.2002.30545

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

1.  Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines.

Authors:  Hadja Fatima Tbahriti; Djamel Meknassi; Rachid Moussaoui; Amar Messaoudi; Lakhdar Zemour; Abbou Kaddous; Malika Bouchenak; Khedidja Mekki
Journal:  World J Nephrol       Date:  2013-05-06

Review 2.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

3.  The Interrelationships among albumin, nutrient intake, and inflammation in elderly recuperative care patients.

Authors:  D H Sullivan; L E Johnson; R A Dennis; P K Roberson; M Heif; K K Garner; M M Bopp
Journal:  J Nutr Health Aging       Date:  2011-04       Impact factor: 4.075

Review 4.  Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors.

Authors:  Manisha Jhamb; Steven D Weisbord; Jennifer L Steel; Mark Unruh
Journal:  Am J Kidney Dis       Date:  2008-06-24       Impact factor: 8.860

Review 5.  Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Expert Opin Investig Drugs       Date:  2008-04       Impact factor: 6.206

Review 6.  Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.

Authors:  A M Macleod; M Campbell; J D Cody; C Daly; C Donaldson; A Grant; I Khan; K S Rabindranath; L Vale; S Wallace
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

7.  Hemodialysis Is Associated With Increased Peripheral Artery Occlusive Disease Risk Among Patients With End-Stage Renal Disease: A Nationwide Population-Based Cohort Study.

Authors:  Chin-Sheng Lin; Sy-Jou Chen; Chih-Chien Sung; Cheng-Li Lin; Shih-Hua Lin; Shu-Meng Cheng; I-Kuan Wang; Wen-Sheng Huang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

8.  Impact of arteriovenous fistula blood flow on serum il-6, cardiovascular events and death: An ambispective cohort analysis of 64 Chinese hemodialysis patients.

Authors:  Zhizhi Hu; Fengmin Zhu; Nan Zhang; Chunxiu Zhang; Guangchang Pei; Pengge Wang; Juan Yang; Yujiao Guo; Meng Wang; Yuxi Wang; Qian Yang; Han Zhu; Wenhui Liao; Zhiguo Zhang; Ying Yao; Rui Zeng; Gang Xu
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

9.  Seroprevalence of a "new" bacterium, Simkania negevensis, in renal transplant recipients and in hemodialysis patients.

Authors:  Andrea Angeletti; Roberta Biondi; Giuseppe Battaglino; Eleonora Cremonini; Giorgia Comai; Irene Capelli; Gabriele Donati; Roberto Cevenini; Manuela Donati; Gaetano La Manna
Journal:  BMC Nephrol       Date:  2017-04-13       Impact factor: 2.388

10.  Correlation between the microinflammatory state and left ventricular structural and functional changes in maintenance haemodialysis patients.

Authors:  Lihua Shi; Jie Song; Xiaodong Zhang; Ying Li; Hui Li
Journal:  Exp Ther Med       Date:  2013-05-28       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.